Drug intelligence / Profile preview

Pt(IV)Ac-POA

Development stage: Preclinical
Modality: Small Molecules
Administration: Not Explicitly Stated; Likely Intravenous Based On Platinum Drug Conventions.

Overview

Pt(IV)Ac-POA is a novel platinum(IV)-based prodrug designed for anticancer therapy. It features (2-propynyl)octanoic acid (POA), a histone deacetylase inhibitor (HDACi), as an axial ligand. The compound acts as a prodrug, undergoing reduction within tumor cells to release cisplatin and the HDACi, thereby generating synergistic antineoplastic effects. Pt(IV)Ac-POA has demonstrated promising antitumor activity in preclinical models of glioma, inducing cell death through multiple pathways at lower concentrations than other platinum analogues and potentially reducing chemoresistance[1][2].

Targets

HDAC (HDAC family)DNA

Beyond the preview

Go deeper on Pt(IV)Ac-POA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pt(IV)Ac-POA.

Explore the full profile